The COVID-19 pandemic reignited global debate over the right to health as a fundamental human right, sharply exposing entrenched inequities in healthcare systems. The pandemic experience underscored how issues like vaccine access, pharmaceutical patent barriers, and the robustness of Universal Health Coverage (UHC) can make the difference between life and death—especially in low- and middle-income countries (LMICs). As the world transitions to a post-pandemic phase, these challenges demand urgent global attention and reform.
Vaccine Inequities
The Scale and Consequences
The pandemic’s vaccine rollout starkly reflected the gap between high-income and lower-income countries. Wealthy nations secured the lion’s share of doses early through bilateral deals, leaving LMICs to rely on initiatives like COVAX for supply. By January 2022, COVAX had delivered 1.1billion doses—a substantial figure, but only a fraction of its original 2billion-dose target and insufficient for the needs of the global South. In some regions, coverage through COVAX was disproportionately low: for example, only 16% of the South Asian population benefited, compared to higher coverage in parts of Latin America and the Caribbean. Countries such as Rwanda (LIC) and Samoa (LMIC) were relative success stories, receiving proportionately high distributions via COVAX, whereas populous countries like India saw far fewer doses per capita. Persistent inequities in both primary and booster vaccine rollouts have been tied to systemic, racial, and socioeconomic disparities, even within high-resource settings—proof that deep-rooted structural determinants continually shape health access outcomes.
Pharmaceutical Patent Barriers
Rapid vaccine development was enabled by unprecedented scientific cooperation and public investment, but access to these medical breakthroughs was stymied by pharmaceutical patent protections. Patent regimes granted monopolies to manufacturers, allowing them to set prohibitively high prices and restrict generic competition, especially in countries least able to afford expensive treatments. Tactics such as extensive “patent thickets” on key drugs (e.g., for chronic conditions and cancers) extended monopolies and delayed the availability of cheaper generics—sometimes for decades. These strategies have been widely critiqued for placing company profits above public welfare and exacerbating global inequity. Both international panels and academic experts have called for reforms, urging the use of competition law and the reevaluation of data exclusivity measures to balance innovation incentives with the public interest in affordable medicines.
The Role of Universal Health Coverage (UHC)
UHC, defined as ensuring that all people have access to needed health services—including essential medicines—without financial hardship, is increasingly recognized as a linchpin for health equity in post-pandemic recovery. UHC frameworks that emphasize rational selection, fair pricing, sustainable financing, and resilient supply chains are essential for strengthening health systems against future shocks. For example, Ghana’s initiatives in revising essential medicines lists, standardizing pricing, and ensuring sustainable financing were associated with better financial protection and improved healthcare access throughout the pandemic. International bodies such as the World Health Organization assert that UHC is the best way to guarantee equitable access to safe, effective, and affordable medicines and health products, and must remain central to global health agendas.
Case Studies from LMICs
In LMICs, access to healthcare during the pandemic was further complicated by weak infrastructure, fragile health systems, and funding shortfalls. Surveys from 39 LMICs found that nearly 19% of households could not access healthcare when needed during the pandemic, with financial barriers cited as the leading reason—especially in the poorest countries, where up to 65% of those foregoing care did so for economic reasons. Additional disruptions included transportation problems, supply chain breakdowns, and reduced quality of care—challenges especially acute for rural and marginalized communities. However, targeted reforms in countries like Ghana, which prioritized evidence-based medicine selection, pricing transparency, and improved financing, demonstrated that policy interventions can meaningfully expand access—especially when part of broader UHC strategies.
The COVAX Initiative
COVAX was the global community’s foremost attempt at ensuring equitable vaccine access by pooling procurement and distribution for member states. While it achieved notable successes, delivering over 800million doses to LMICs by early 2022, it still fell short of its goals due to supply constraints, export bans, and funding gaps. For the 67 low-income countries relying on COVAX as their primary vaccine source, these delays illustrated just how fragile global solidarity can be in the face of competing national interests.
Policy Suggestions for Global Equity in Future Health Crises
- Reform Patent and Intellectual Property Rules: Implement flexibilities to allow for compulsory licensing, encourage voluntary licensing for generics, and target anti-competitive patent practices to enable affordable, wider-access generic manufacturing during crises.
- Accelerate UHC Implementation: Countries should prioritize UHC by investing in health infrastructure, rational medicine selection, transparent pricing strategies, and resilient logistic chains, all tailored for both routine and emergency contexts.
- Strengthen Global Cooperation: Reform existing international agreements (like the recent Pandemic Agreement) so that human rights and access to healthcare are binding obligations, not just aspirations.
- Bolster Funding for COVAX and Similar Initiatives: Ensure sustainable, predictable, and expanded funding sources so pooled procurement mechanisms can act quickly and fairly, independent of geopolitical pressures.
- Enhance Data Transparency and Accountability: Create clear monitoring frameworks for public and civil society oversight, with specific equity- and rights-based indicators for tracking countries’ pandemic preparedness and response.
- Support Health Workforce and Supply Chains in LMICs: Reinforce training, recruitment, and retention of health workers; invest in local health manufacturing and distribution to reduce reliance on global supply bottlenecks.
The right to health, including access to medicines, is not simply a moral imperative but a matter of global security and justice. The pandemic’s legacy must be one of reform: expanding UHC, correcting inequities in vaccine and medicine access, restructuring intellectual property regimes, and embedding rights-based accountability in pandemic governance. Future preparedness, resilience, and solidarity depend on whether these lessons are recognized—and acted upon—worldwide.
